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Abstract
Myotonic dystrophy (MD) is characterized by myotonic 
phenomena and progressive muscular weakness. 
Involvement of the gastrointestinal tract is frequent 
and may occur at any level. The clinical manifestations 
have previously been attributed to motility disorders 
caused by smooth muscle damage, but histologic 
evidence of alterations has been scarce and conflicting. 
A neural factor has also been hypothesized. In the upper 
digestive tract, dysphagia, heartburn, regurgitation and 
dyspepsia are the most common complaints, while in 
the lower tract, abdominal pain, bloating and changes 
in bowel habits are often reported. Digestive symptoms 
may be the first sign of dystrophic disease and may 
precede the musculo-skeletal features. The impairment 
of  gastrointestinal function may be sometimes so 
gradual that the patients adapt to it with little awareness 
of symptoms. In such cases routine endoscopic and 
ultrasonographic evaluations are not sufficient and 
targeted techniques (electrogastrography, manometry, 
e lectromyography, funct iona l u l t rasonography, 
scintigraphy, etc .) are needed. There is a low correlation 
between the degree of skeletal muscle involvement and 
the presence and severity of gastrointestinal disturbances 
whereas a positive correlation with the duration of the 
skeletal muscle disease has been reported.
The d r ug s r e c ommended f o r t r e a t i n g t h e 
gastrointestinal complaints such as prokinetic, anti-
dyspeptic drugs and laxatives, are mainly aimed at 
correcting the motility disorders.
Gastrointestinal involvement in MD remains a 
complex and intriguing condition since many important 
problems are still unsolved. Further studies concentrating 
on genetic aspects, early diagnostic techniques and the 
development of new therapeutic strategies are needed 
to improve our management of the gastrointestinal 
manifestations of MD.
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Myotonic dystrophy (MD) is an autosomal dominant 
genetic disorder[1]. It is caused by an unstable trinucleotide 
repeat expansion containing cytosine-thymidine-
guanosine (CTG)n, located in the 3’ untranslated region of  
chromosome 19q13.3. The CTG trinucleotide is repeated 
in the normal population from 5 to 36 times[2,3], but has 
been found to be expanded up to 2 000 times in MD 
patients[4,5]. This amplification is correlated to the severity 
of  the disease. Patients can be divided into four groups 
based on the number of  CTG repeats. Group E1 (50-100 
CTG repeats) may have either the minor or the classical 
form of  MD, group E2 (500-1 000 CTG repeats) have 
the classical form of  MD, group E3 (1 000-1500 CTG 
repeats) have the classical form of  MD with onset during 
childhood, and group E4 (more than 1 500 CTG repeats) 
are affected with the congenital form of  MD[6].
Although MD is primarily characterised by myotonic 
phenomena and progressive muscular weakness, multi-
system involvement is often present, taking the form 
of  cardiac conduction abnormalities, cognitive deficits, 
cataracts and diabetes, as well as endocrine, sexual 
and reproductive disturbances [1]. Involvement of  the 
gastrointestinal (GI) tract is frequent, and may occur at any 
level from the pharynx to the anal sphincter. Dysphagia, 
heartburn, emesis, regurgitation, coughing while eating and 
dyspepsia are the most common complaints involving the 
upper digestive tract, while abdominal pain and bloating, 
changes in bowel habits (diarrhoea or constipation) and 
dyschezia are common signs of  impairment of  the lower 
digestive tract [7-9]. These clinical manifestations have 
generally been attributed to motility disorders caused 
by striated and more rarely, smooth muscle damage[10],  
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although recent studies suggest that neurological 
alterations may also play a role[11,12].
There appears to be little correlation between the 
degree of  skeletal muscle involvement and the presence 
and severity of  the gastrointestinal disturbance, but 
some authors have reported a positive correlation with 
the duration of  the skeletal muscle disease[13, 14]. In some 
patients the impairment of  gastrointestinal function is so 
gradual that they adapt to it with little or no awareness 
of  any disturbance and only a thorough anamnesis may 
elicit the recall of  possible symptoms[12]. In such patients, 
routine endoscopic and ultrasonographic evaluations are 
of  little value and only highly sensitive, targeted techniques 
such as electrogastrography, manometry, electromyography, 
functional ultrasonography, compartmental scintigraphy, 
etc. may help to reveal the true extent of  the involvement. 
In this review, the available data on the pathophysiologic 
mechanisms of  GI involvement in myotonic dystrophy, 
their impact on clinical manifestations of  the disease, and 
the tests that can be used to detect them, are discussed in 
turn for each segment of  the gastrointestinal tract.
PHARYNX AND ESOPHAGUS
Because most complaints by MD patients focus on 
the pharynx and esophagus, which can be quite easily 
investigated, these are the manifestations that have been 
most thoroughly studied thus far. MD patients often report 
dysphagia, sometimes associated with coughing while 
eating, chest pain, regurgitation and heartburn. Different 
studies have reported a prevalence of  dysphagia ranging 
from 25% to 80%[9, 12, 15, 16].This is usually considered by 
both patients and doctors to be the most serious symptom 
of  MD, probably because it is associated with a high 
incidence of  recurrent pulmonary infection[17].
Manometry is useful to detect motility disturbances, 
which show in the form of  asymmetric contractions of  the 
pharynx and weak contractions of  the upper esophageal 
sphincter (UES)[14]. Studies have reported a reduced basal 
UES pressure in MD patients compared to controls[11] , 
although the prevalence and duration of  UES relaxation 
during swallowing are similar between the two groups and 
more significantly, no difference in the residual pressure 
during relaxation has been found[11, 12,1 8] .
In the esophageal body significant decreases in the 
peristaltic amplitude and/or simultaneous waves have 
often been reported[12, 18]. A study of  14 MD patients 
showed a marked decrease in the median amplitude of  
the contractions at every level of  the esophagus. A higher 
percentage of  non-transmitted and dropped contraction 
sequences after swallowing has been observed in patients 
compared to controls, 43% exhibited complete atony 
of  the esophageal body with a scleroderma-like pattern 
and no detectable esophageal contractions. In this series, 
although manometry showed impaired esophageal motor 
function in 71% of  the patients, 50% of  these were quite 
asymptomatic[18].
Involvement of  the lower esophageal sphincter 
(LES) is a somewhat more complex matter. Modolell et 
al.[12] failed to detect a significant difference in basal LES 
pressure between patients and controls, only reporting 
some cases of incomplete LES relaxation[12]. In contrast, 
other studies have found a significantly reduced resting 
tone, competence, and area vector volume of  the LES 
in MD patients than in controls[9, 18]. These data suggest 
that some alteration in the smooth muscle may take place, 
leading to a higher risk of  developing gastroesophageal 
reflux disease (GERD)[18].
Esophageal spasm and segmental dilatation can be seen 
on x-rays, while radiological and scintigraphic techniques 
are useful for detecting both a lack of  tone and a reduced, 
ineffective or absent peristalsis[12, 15, 19].
Most authors hold that pharyngo-esophageal myotonia, 
or problems with post-contraction relaxation, should no 
longer be considered as a typical feature of  esophageal 
involvement[12, 18]. A myotonic response to pharyngeal 
contractions has been reported by Siegel et al [20], but 
we now know that this is due to limitations in x-ray 
technology at the time when the study was conducted.
It has been hypothesized that distal esophageal 
impairment may be myogenic in origin and abnormalities 
in both the striated and smooth muscle fibers may play 
a role in MD. However, the histologic data published 
to date have failed to demonstrate any alteration in the 
esophageal smooth muscle fibers[19]. Marked atrophy of  
the esophageal striated muscle, but only small changes in 
the smooth muscle were observed in a patient reported by 
Jéquier et al[21]. In another case, using electron microscopy 
to study the esophagus, Ludatscher et al[22] detected mild 
degenerative changes with disoriented filaments of  the 
smooth muscle.
Smooth muscle damage could also explain the reduced 
LES tonic resting pressure and the elevated frequency of  
heartburn observed in MD patients. Unfortunately, most 
of  the reported cases did not include an upper digestive 
tract endoscopic examination or a 24-h pH-metry to 
determine the presence and degree of  GERD[18] . 
Recently some authors have suggested that a combined 
myopathic - neuropathic etiology could provide a more 
satisfactory explanation for the pharyngo-esophageal 
symptoms of  MD, but at present this remains speculative 
[12]. One proposed hypothesis is that decrease in the normal 
amplitude of  the peristaltic waves could reflect the inability 
of  the muscle to contract under normal neural control. 
On the other hand, uncoordinated motor activity in the 
presence of  a normal amplitude contraction could indicate 
a lack or defect in neural control[12]. This hypothesis is not 
supported by the study of  Eckardt et al[19], who failed to 
detect any neuropathic alterations in MD patients. 
However, there are data to suggest that there is no 
association between the degree of  muscular disability and 
motor abnormalities of  the pharynx and esophagus, the 
presence and severity of  dysphagia, or other esophageal 
symptoms[12]. For example, manometric findings are 
not significantly different between symptomatic and 
asymptomatic patients or in patients with different degrees 
of  striated muscular involvement[9, 12, 18, 19]. In particular, 
in a study of  18 MD patients Modolell et al[12] showed 
that while severe pharyngo-esophageal abnormalities 
are present in all patients, symptoms are spontaneously 
reported by only 30% of  them. This figure rose but only 
to 55%, when the patients were specifically questioned on 
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this point.
These conflicting reports may be explained by the 
fact that the tongue and pharyngeal muscles can contract 
sufficiently to push a bolus through the UES into the 
esophagus, after which the force of  gravity is enough 
to complete the swallowing process. Moreover, because 
of  the slow evolution of  the disease, MD patients may 
develop compensatory mechanisms and thus gradually 
adapt to the impairment of  their esophageal function[18]. 
STOMACH AND DUODENUM
MD patients frequently complain of  dyspeptic symptoms 
such as early satiety, nausea, vomiting, and epigastric 
pain[9]. Radiographic, manometric, ultrasonographic and 
scintigraphic evidence of  decreased peristaltic activity 
causing the delayed emptying of  liquids and solids, visceral 
dilatation, gastric bezoars and even gastroparesis have been 
reported[10, 13, 23-25] . 
Kuiper et al [23] have described the case of  an MD 
patient who developed symptoms suggestive of  gastric 
retention. Radiological and endoscopic examination 
revealed polypoid masses, cytologic washing showed 
them to be food concretions, probably a consequence of  
abnormal gastric motility[23].  More recently, scintigraphic 
studies by Ronnblom et al[25] indicate a delayed emptying 
of  the stomach in MD patients with dyspeptic symptoms, 
demonstrated by a prolonged lag phase, a slower emptying 
rate, and a prolonged T/2.
Bellini et al [13] used ultrasound to evaluate gastric 
emptying abnormalities and their relationship with the 
severity and duration of  the disease in 11 MD patients 
without dyspeptic symptoms. They found that MD 
patients and healthy subjects exhibit comparable fasting 
and maximal antral areas. The findings that (i) the basal 
and maximal post-prandial values for the gastric antral 
area between MD patients and controls were quite similar, 
and (ii) the time required to reach the maximal post-
prandial values did not differ in the two groups, are in 
agreement with the fact that the patients studied were not 
dyspeptic[13]. Analogous results have been reported for 
a group of  non-dyspeptic patients affected by systemic 
sclerosis[26]. 
Indeed, increased antral dimensions have been reported 
in patients with functional dyspepsia[27,28], suggesting that 
such abnormalities may play a role in the pathogenesis of  
the dyspeptic symptoms in MD. In Bellini’s study[13], the 
final emptying time of  the MD patients was longer than 
that of  healthy volunteers and was clearly correlated with 
the disease duration, but was independent of  both the 
CTG expansion size and the patients’ disability class. 
It is not surprising that patients without dyspeptic 
symptoms may have delayed gastric emptying. Indeed the 
association between delayed gastric emptying and upper GI 
complaints is still under debate[29]. Other abnormalities in 
gastric motor function, such as impaired accommodation 
of  the proximal stomach[30, 31], abnormal distribution of  the 
gastric contents[31], gastric dysrythmias[32, 33], and a lack of  
antro-pyloro-duodenal coordination[34], could play a role in 
the pathogenesis of  dyspeptic symptoms in these patients.
Bellini et al[13] have confirmed that a direct relationship 
between disease severity and the impairment of  GI motor 
functioning remains to be demonstrated, since there is no 
significant difference in gastric emptying between patients 
with different degrees of  skeletal muscle involvement. 
These results appear to agree with previous studies, 
demonstrating that skeletal muscular damage and gastric 
motor disturbances can progress independently[14]. On the 
other hand, the direct correlation between final emptying 
time and disease duration suggests that the impairment of  
gastric emptying may evolve over time.
The delayed gastr ic emptying in MD could be 
explained by the muscular disease itself. Unfortunately no 
definitive conclusions can be drawn on this point because 
the histological evidence remains limited. Gastric smooth 
muscle is only rarely affected[7, 8] and as we have already 
seen in the esophagus, when damage occurs it appears 
to be similar although earlier and more severe in nature 
to that occurring in skeletal muscle with severe fatty 
infiltration[35] . However, a sufficiently large study focusing 
on the gastric smooth muscle in MD patients is still 
lacking. It would be important to determine whether the 
two types of  muscle tissue may be damaged to different 
degrees in the same subjects.
Recent reports suggest that, as in the pharynx and 
esophagus, muscle involvement alone is not sufficient to 
explain the altered digestive function in the stomach and 
duodenum of  MD patients. Impaired nervous conduction 
as well as altered GI hormone secretions could be involved 
in the motor abnormalities[25]. For example, changes 
in the electrical impulses controlling duodenal activity 
could explain the chronic intestinal pseudo-obstruction 
occasionally reported in MD. Likewise a reduction in the 
electrical control of  gastric activity could be a possible 
cause of  delayed gastric emptying[25].
An electrogastrographic study carried out by Ronnblom 
et al[36] on 10 patients showed that gastric electric cycling 
activity manifested as bradygastria, tachygastria and a less 
stable frequency of  the gastric signal are reduced compared 
with control subjects. The presence of  an abnormal EGG 
in MD patients supports the hypothesis that the disease 
is a systemic disorder, affecting not only the muscles 
but also other tissues. Ronnblom et al[36] then studied the 
gut hormone profile in the same group of  patients and 
found that the post-prandial secretion of  motilin and 
glucagone-like peptide-1 (GLP-1) is decreased in MD 
patients. Since motilin triggers the antral phase III activity 
of  the migrating motor complex and accelerates gastric 
emptying, reduced motilin secretion could cause delayed 
gastric emptying. In contrast, low post-prandial GLP-1 
secretion is probably a result of  delayed gastric emptying, 
i.e. a consequence rather than a cause of  the disease. The 
patients with the most markedly delayed gastric emptying 
showed abnormal gastric electric activity and an abnormal 
post-prandial gut hormone profile. Both factors may 
contribute to altering gastric functioning. These findings 
indicate a partial dysregulation of  the GI endocrine 
system in MD patients rather than a disorder of  the entire 
digestive endocrine system. This conclusion is supported 
by an immunohistochemistry study carried out earlier 
by the same authors on the different types of  duodenal 
endocrine cells in MD patients affected with diarrhoea[37]. 
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They reported that the duodenal endocrine cell area 
containing the cells that produce serotonin, gastrin/CCK, 
secretin, GIP and somatostatin, is significantly increased. 
There are various possible explanations for this finding. 
The increased cell area may be a primary phenomenon or a 
consequence (via a feed-back mechanism) of  the synthesis 
of  defective and biologically inactive peptides or the result 
of  a reduced receptor sensitivity of  the effector cells and a 
malfunctioning effector organ. 
If  the increase in the number of  endocrine cells is a 
primary disorder, it could play a role in the gastrointestinal 
manifestations of  MD. However, even if  it is merely 
a secondary phenomenon, a possible link can still be 
hypothesized, because the intestinal peptides may act on 
many different organs. Further studies are needed to shed 
light on this intriguing issue. At present, no correlation has 
been found between the increase in the duodenal cell area 
and the severity of  the disease[37].
Different drugs, particularly prokinetics, have been 
proposed to treat the dyspeptic symptoms and motor 
disturbances in MD patients. In their study of  16 patients 
with delayed gastric emptying of  solids and liquids, 
Horowitz et al [14] showed that oral administration of  
10 mg of  metoclopramide 3 times per day can improve 
the gastric emptying of  both a solid and a liquid meal, 
but has no effect on esophageal emptying. In another 
study the same authors tested the efficacy of  cisapride 
(10 mg, 4 times per day) and reported that it improves both 
gastric emptying and digestive symptoms such as nausea, 
vomiting, early satiety, abdominal distension and pain[38]. 
Metoclopramide also seems to be effective in improving 
gastric emptying in MD patients with gastroparesis[24]. Its 
effect may be due to the local release of  acetylcholine and/
or the hypersensitivity of  the smooth muscle cells to this 
transmitter, and/or a reduction in the inhibitory effect of  
dopamine on gastric motility[14, 24, 39]. 
Ronnblom et al[25] administered erythromycin (100 mg, 
2 times per day, before lunch and dinner) to dyspeptic 
MD patients over a period of  4 wk. The rationale for the 
use of  erythromycin, which has been proved effective in 
accelerating gastric emptying in diabetic gastroparesis, lies 
in its agonistic action on the motilin receptors[10]. No effect 
on gastric emptying and no immediate improvement in 
symptoms were observed, although by the end of  the 4-wk 
period a slight improvement in nausea and early satiety and 
a marked improvement in diarrhoea were noted by some 
patients. The authors reported that overall the treatment 
is effective possibly due to the positive effects of  the drug 
on other GI symptoms, such as bacterial overgrowth in the 
ileum, which causes diarrhea by inhibiting the absorption 
of  bile acid[25].
SMALL AND LARGE INTESTINE
Diarrhea, sometimes accompanied with malabsorption, 
steatorrhea, and crampy abdominal pain, are frequent 
complaints in MD patients[9]. Paralytic ileus has also 
been reported[40, 41]. The pain may be located in any 
part of  the abdomen, with no specific characteristics or 
eliciting factors. Episodic diarrhoea is the single most 
common complaint (present in up to 33% of  cases). It 
is often disabling and may have a marked impact on the 
patient’s social life, especially when combined with anal 
incontinence[9].
Diarrhea and possibly malabsorption, have been 
attributed to reduced peristaltic activity leading to 
bacterial overgrowth [10]. Anaerobic bacteria seem to 
be the principal contaminating agents. Their ability to 
deconjugate bile acids, thereby causing defective uptake in 
the terminal ileum, could be the main cause of  diarrhea[25, 
42]. Norfloxacine, either alone or in combination with 
cholestyramine, can alleviate this symptom in some 
patients. Other possible mechanisms of  diarrhea, such as 
the reduced secretion of  pancreatic amylase, have been 
hypothesized but not yet been demonstrated, and further 
evidence is needed to shed light on this issue[42].
Radiological studies have demonstrated reduced or 
absent peristaltic and/or segmentary activity with delayed 
intestinal transit[43-45]. Megacolon, sigmoid volvulus and 
segmental narrowing due to myotonic contractions have 
also been reported[43, 46-52].
Megacolon with the accompanying risk of  ileus, 
volvulus and rupture, is a significant complication and must 
be kept in mind during the management of  MD patients 
who are usually at higher risk of  complications during 
anesthesia and surgical operations than normal subjects. 
The pathophysiological mechanisms underlying megacolon 
are not entirely clear, but probably smooth muscle damage 
is not the only factor involved. An electron microscopy 
study of  an MD patient with megacolon showed that the 
myenteric plexus is degenerated with a paucity of  neurons 
and fragmented axons. Glial cells are increased in number 
with vacuoles containing electron-dense material. Swelling 
of  the mitochondria, distension of  the endoplasmic 
reticulum and the accumulation of  free ribosomes in the 
cytoplasm are also observed. The neurons are described 
as being “fewer, and the argyrophilic ones smaller, with 
less prominent processes and poor staining quality.” The 
number of  nerve fibers exhibiting reactivity to substance P 
and enkephalin in the muscolaris externa is decreased, while 
normal smooth muscle cells are reported[52]. 
In concurrence with pregnancy or episodes of  
gastroenteritis, MD patients have been reported to suffer 
from recurrent intestinal pseudo-obstruction presenting 
with nausea, vomiting, abdominal cramps, distension and 
sometimes, constipation[53, 54]. However, such complications 
may occur during any stage of  the disease and may even 
precede significant skeletal muscle weakness by 15 years. 
Recently, an MD patient with pseudo-obstruction and 
partial malrotation of  the intestine has been reported[55], 
although it should be noted that this association has never 
been observed before and could represent an isolated 
case[56].
Manometric studies of  the small intestine (jejunal 
manometry) in MD patients have shown low amplitude 
contractions of  the migrating motor complex during 
phases 2 and 3, with high frequency activity during phase 
2 and retrograde propagation and interruption of  the 
contractions during phase 3. Low amplitude post-prandial 
contractions and myotonic phenomena have also been 
reported. A disturbance of  the mechanoreceptors that 
link the circular muscle layer with the enteric nerves and 
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provide the stimulus for the propagation of  migrating 
motor complex phase 3 activity has been hypothesized to 
explain these phenomena[57].
Very few manometric studies of  the colon have been 
conducted and the results are conflicting. Some report 
an absence of  the normal rhythmic pressure variation in 
the descending colon[43], while others have failed to detect 
any motility abnormalities in the sigmoid colon[58]. In any 
case, intestinal motility disturbances are detectable in both 
symptomatic and asymptomatic subjects, raising doubts 
as to the actual role they play in the pathogenesis of  MD. 
The absence of  a correlation between disease severity and 
the presence of  symptoms has also been confirmed in the 
intestinal tract[57]. 
Only a small number of  histologic studies of  the 
muscular layer of  the small intestine are now available. 
They describe the cells as being swollen, fragmented, 
partially destroyed, or decreased in size, and replaced by 
fats, quite similar to the abnormalities reported for the 
skeletal muscles[35, 59]. Biopsies of  the mucosa usually show 
normal histologic patterns[37, 43, 60, 61], although a case of  
a patient with intestinal villous atrophy and collagenous 
sprue has been reported by Woods et al[62]. The authors’ 
suggestion that this type of  malabsorption may be 
frequent in MD patients has not yet been confirmed. 
RECTOANAL REGION
Although constipation often associated with dyschezia is 
common, since some patients represent a serious problem, 
the most burdensome and disabling problem affecting MD 
patients may be fecal incontinence[9, 63, 64]. Up to 66% of  
MD patients suffer occasional fecal incontinence, while 
more than 10% report fecal incontinence one or more 
times a week. The frequency of  urinary incontinence 
seems to have no difference between MD patients and 
control subjects[9, 65].
Although the procedure i s s imple and low in 
invasiveness, manometric studies of  the rectoanal region 
are not often performed in MD patients. Some studies 
report a decrease in both the resting pressure (based on 
the tonic activity of  the internal anal sphincter) and the 
squeezing pressure (exerted by the phasic activity of  the 
external anal sphincter)[65-67]. Others have failed to detect 
any significant modification in the resting pressure and 
only a slight, statistically insignificant decrease in the 
squeezing pressure[11].
Lecointe e t a l [11] found that the ampli tude and 
duration of  the recto anal inhibitory reflex (RAIR) in 
response to rectal distension are markedly decreased in 
MD patients. This could be explained, however, by a 
prolonged myotonic contraction of  the striated external 
anal sphincter muscles[67], which could obscure the 
manometric signal indicating the normal internal anal 
sphincter relaxation response to rectal distension. Due to 
this myotonic phenomenon, the duration of  the rectoanal 
contractile reflex (RACR) is longer in patients than in 
controls[11]. According to Hamel Roy et al[68], the amplitude 
of  this myotonic response is decreased by pudendal nerve 
blockade, suggesting the possibility of  at least a partial 
neural reflex response. Pudendal nerve terminal motor 
latencies are normal in these patients, confirming the 
absence of  a neurogenic lesion[67, 69]. Finally, it was reported 
that the maximum tolerable volume at rectal distension is 
significantly lower in MD patients than in controls[11]. 
Anorectal motility disturbances are as frequent 
as pharyngo-esophageal disturbances, the degree of  
involvement of  the upper and distal portions of  the 
gastrointestinal tract may be closely correlated both 
quantitatively and qualitatively[11]. It has been shown that 
anorectal motility and esophageal motility are altered in a 
similar number of  patients[11]. 
Although the prevalence of  altered motility is high, 
symptoms such as anal incontinence, diarrhoea and/or 
abdominal pain have been found in a small number of  
patients, suggesting that there is a close relationship 
between smooth and striated muscle motor function 
in MD but only in the gastrointestinal tract, where 
smooth and striated muscle abnormalit ies may be 
interdependent[11]. Unfortunately, there are no histologic 
data to back up this intriguing hypothesis.
Eckardt et al[66] studied the external anal sphincter 
using electromyography and have found myopathic 
potentials with myotonia. Herbaut et al.[65] reported a 
decreased duration and amplitude of  the motor units in 
the external anal sphincter and the puborectalis muscle 
of  MD patients with fecal incontinence, suggesting that 
there may be a myopathic component to the pathology. 
In 25% of  these patients, polyphasic high-amplitude 
motor units were also present, indicating the probable 
presence of  a neuropathic lesion. Taken together, the data 
suggest that both the striated external anal sphincter and 
the smooth internal anal sphincter may be altered in MD, 
even if  previous histologic examinations have reported 
pathological findings only in the striated muscle[66]. More 
recently, Abercrombie et al[67] used electron microscopy 
to study the anal sphincter in two siblings with MD and 
found that the external anal sphincter is atrophic in both 
patients, with marked fibrosis and a high variation in the 
diameter of  the fibres as well as the striated muscle almost 
entirely substituted by smooth muscle cells deriving from 
the internal sphincter. These cells are all different in 
size and electron density separated by large amounts of  
fibrous connective tissue. Some show features suggestive 
of  dedifferentiation into myofibroblasts. The puborectalis 
biopsies revealed an analogous decrease in the amount 
of  normal striated fibres with pronounced fibrosis. Some 
of  the fibres were hypertrophic with increased central 
nucleation and many showed sarcoplasmic masses. 
Moreover, type 1 fibres were markedly prevalent (99%). 
In the ano-rectal region, no close correlation between 
motor abnormalities and overt symptoms has been found, 
although defecatory behaviour is often severely altered in 
these patients. 
Constipation in MD patients is usually treated with 
prokinetics, laxatives and enemas [15, 70], while medical 
treatment with procainamide (300 mg twice a day) has been 
proposed for fecal incontinence[71]. Surgery to treat fecal 
incontinence has been attempted, but post-anal repair only 
temporarily improves the defecatory function[67]. Treating 
and curing defecatory problems in MD patients remain a 
difficult challenge. Rehabilitation involving a combination 
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of  volumetric rehabilitation, electroanalytical stimulation, 
kinesitherapy and biofeedback, can be effective in those 
patients not suffering from severe damage to the pelvic 
floor muscle[72,73].
CONCLUSIONS
Since MD is a relatively rare disease, most of  the papers 
published are hampered by the bias arising from the low 
number of  patients studied. Many report just one or two 
cases, and very few involve series of  more than 10 patients. 
Gastrointestinal involvement is frequently observed in 
MD patients and digestive complaints may be the first 
sign of  the disease. According to Ronnblom et al[9], 25% 
of  patients consider their gastrointestinal problems 
as the most disabling consequence of  MD, 28% have 
digestive symptoms that may appear up to ten years 
before the typical musculoskeletal features. During this 
period the impairment of  the digestive functions may be 
so gradual that patients unconsciously adapt to them by 
compensatory mechanisms, thus masking the symptoms[18, 
74]. They may even develop a higher pain threshold (visceral 
hypoalgesia) similar to that seen in diabetic gastroparesis[75]. 
For these reasons, patients often do not undergo a 
thorough examination of  the digestive tract, while at the 
same time they may be subjected to a broad battery of  
other examinations because of  multi-system involvement. 
Thus, a careful assessment of  the digestive tract may be 
performed only when the symptoms have become severe, 
although reliable, non-invasive or minimally invasive 
techniques such as ultrasonography, scintigraphy, breath 
test and cutaneous electrogastrography are available[13].
Little correlation has been found between the degree of  
skeletal muscle damage and gastrointestinal disturbances[12, 
14], while there does appear to be a relationship between 
the severity of  GI involvement and the duration of  the 
disease[13]. Nevertheless, the pathophysiologic mechanisms 
of  digestive motor disorders certainly suggest that there 
is damage to the striated muscles in the upper and lower 
portions of  the gastrointestinal tract. Histologic evidence 
of  smooth muscle alterations is scarce and conflicting[12, 
14], although some authors have hypothesized that smooth 
muscle damage may occur earlier and is more severe than 
striated muscle changes[10].
Moreover, some authors suggest that a common 
mechanism may be the generat ion of  the motor 
abnormalities in both the smooth and striated muscles. For 
example, Lecointe et al[11] studied the esophagus and the 
rectoanal region of  MD patients and found that alteration 
in the smooth muscle is closely related with that in striated 
muscle, at least in the digestive tract. 
A neural factor could also be involved in the digestive 
symptoms of  MD patients. Neural dysfunctions, such 
as an alteration in the non-adrenergic, non-cholinergic 
neuronal control of  the GI tract, have been suggested 
to explain the symptoms and instrumental findings 
that may be present even in the absence of  definite 
histologic damage. Nitric oxide (NO) can mediate non-
adrenergic, non-cholinergic nerve-induced relaxation and 
hyperpolarization of  the smooth muscle in the digestive 
tract[76]. NO is produced from L-arginine via NO synthase, 
a key enzyme that is expressed in the myenteric plexus, 
motor neurons and myenteric fetal interneurons[77-80]. Thus, 
the NO molecule seems to be common in both the striated 
and smooth muscles, the inhibition of  NO synthase 
could alter the motor parameters in a manner consistent 
with the observations of  Lecointe et al[11]. This “neuronal 
hypothesis” can explain the absence of  histologic 
abnormalities in the smooth muscle of  MD patients. In 
addition, it could explain the degeneration and decreased 
number of  argyrophilic neurons in the colonic myenteric 
plexus of  an MD patient affected with megacolon[52].
Gastrointestinal involvement in MD remains a complex 
and interesting condition. Given the limited data available, 
there are very few certainties and many important 
questions to be solved [81]. The relationship between 
myotonic dystrophy, gastrointestinal motility and clinical 
symptoms needs to be investigated in greater depth. 
Studies should begin early in their disease course, using non-
invasive diagnostic techniques and concentrating on the 
genetic and histologic aspects of  each case. Such efforts 
can improve our understanding of  the pathophysiology of  
the digestive system involvement in MD and speed up the 
development of  new therapeutic strategies to manage this 
difficult condition.
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